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Fear acquisition and extinction are valid models for the etiology and treatment of
anxiety, trauma- and stressor-related disorders. These disorders are assumed to involve
aversive learning under acute and/or chronic stress. Importantly, fear conditioning and
stress share common neuronal circuits. The stress response involves multiple changes
interacting in a time-dependent manner: (a) the fast first-wave stress response [with
central actions of noradrenaline, dopamine, serotonin, corticotropin-releasing hormone
(CRH), plus increased sympathetic tone and peripheral catecholamine release] and
(b) the second-wave stress response [with peripheral release of glucocorticoids (GCs)
after activation of the hypothalamus-pituitary-adrenocortical (HPA) axis]. Control of fear
during extinction is also sensitive to these stress-response mediators. In the present
review, we will thus examine current animal and human data, addressing the role of stress
and single stress-response mediators for successful acquisition, consolidation and recall
of fear extinction. We report studies using pharmacological manipulations targeting
a number of stress-related neurotransmitters and neuromodulators [monoamines,
opioids, endocannabinoids (eCBs), neuropeptide Y, oxytocin, GCs] and behavioral stress
induction. As anxiety, trauma- and stressor-related disorders are more common in
women, recent research focuses on female sex hormones and identifies a potential role
for estradiol in fear extinction. We will thus summarize animal and human data on the role
of estradiol and explore possible interactions with stress or stress-response mediators in
extinction. This also aims at identifying time-windows of enhanced (or reduced) sensitivity
for fear extinction, and thus also for successful exposure therapy.
Keywords: fear extinction, stress, monoamines, glucocorticoids, opioids, endocannabinoids, estradiol, exposure
therapy
INTRODUCTION
Classical fear conditioning (consisting of fear acquisition and extinction) is an influential
experimental model to study emotional learning and memory. In fear acquisition, an initially
neutral stimulus (cue or context) is paired with an aversive unconditioned stimulus (US)
capable of eliciting a fear response (e.g., Phillips and LeDoux, 1992). After several pairings
in the acquisition phase, the neutral stimulus becomes a conditioned stimulus (CS), now
capable of eliciting a conditioned fear response (CR). Fear extinction is induced when the
CS is repeatedly presented without the aversive outcome (US), resulting in a decline of
CRs. In rodents, fear responses are typically assessed via freezing behavior (e.g., Bouton
and Bolles, 1980; Fanselow and Helmstetter, 1988) or the fear-potentiated startle reflex
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(e.g., Brown et al., 1951; Davis, 1986). In humans, learning
indicators used alone or combined include: skin conductance
responses (SCRs), fear-potentiated startle, functional imaging
data, as well as subjective ratings of US expectancy and/or CS
valence/arousal (e.g., Grillon et al., 2004; Stark et al., 2006;
Blechert et al., 2007; Milad et al., 2010; Soeter and Kindt,
2012; Bentz et al., 2013). Fear conditioning is highly adaptive,
as it enables the organism to effectively and rapidly learn to
predict danger using context information and environmental
cues. However, fear learning can become dysfunctional if the
organism continues to display fear responses in the absence of
danger.
Both, fear acquisition and extinction, are valid to model
features of anxiety disorders as well as trauma- and stressor-
related disorders (such as posttraumatic stress disorder, PTSD).
Specifically, fear acquisition can serve to model features of the
etiology of these disorders. Correspondingly, simple phobias,
social phobia, panic disorder, and PTSD are characterized
primarily by dysregulated fear responses (Ehlers and Clark,
2000; Parsons and Ressler, 2013). Moreover, these disorders
are characterized by deficits in fear extinction. This inability to
inhibit fear responses is assumed to largely contribute to the
maintenance of anxiety disorders (Lissek et al., 2005; Delgado
et al., 2006; Mineka and Zinbarg, 2006; Mineka and Oehlberg,
2008), as well as trauma- and stressor-related disorders (e.g.,
Ehlers and Clark, 2000; Mineka and Oehlberg, 2008; Cover et al.,
2014). PTSD is assumed to be related to and even caused by a
failure to consolidate and retrieve memory for fear extinction
(Quirk and Mueller, 2008). Correspondingly, patients with
anxiety and especially trauma-related disorders show deficits in
fear extinction learning and extinction recall (Lissek et al., 2005;
Blechert et al., 2007;Michael et al., 2007;Milad et al., 2008, 2009b;
Jovanovic et al., 2010; Glover et al., 2011; Norrholm et al., 2011;
Inslicht et al., 2013).Moreover, extinction learning also serves as a
model for exposure techniques in behavioral therapy (e.g., Milad
et al., 2014).
The development of anxiety disorders and especially
PTSD can be conceptualized as learning under severe
stress. Stress is a state of actual or potential disruption in
the individual’s internal/external environment registered
by the brain and caused by factors we call stressors (Joëls
and Baram, 2009). Stress leads to activation of the stress
response—including activation of the central and peripheral
nervous system and release of neuromodulators, hormones
and transmitters—the stress-response mediators—in the brain
and periphery. The stress response enables the organism
to deal with the challenge by increasing central arousal,
mobilizing energy, increasing cardiovascular tone, inhibiting
costly processes such as reproduction, feeding, and digestion,
and by modifying immune responses (Sapolsky et al., 2000;
Chrousos, 2009). Thus, stress and the stress response are
important for survival and are adaptive in nature. However,
in some circumstances stress may cause pathology, as is
the case in PTSD and other trauma- and stressor-related
disorders. Traumatic situations not only include specific
fear-related behaviors (e.g., flight, freezing) but also a
significant amount of the less specific stress response. Thus,
understanding how stress, the stress response, and specific
stress-response mediators contribute to pathological changes
seen in PTSD—such as impaired extinction—is of special
importance. Moreover, understanding what conditions
allow for normal functioning despite (traumatic) stress
could advance our understanding of resilience and advance
prevention. Last but not least, PTSD itself is accompanied
by heightened stress (Maren and Holmes, 2016) and is
also associated with changes of the stress system (e.g.,
Lupien et al., 2009). Both facts could interfere with the
success of extinction-based exposure therapy. Consequently,
examining effects of stress and single stress-response
mediators on fear extinction could help improve treatment
efficacy or even provide new targets for pharmacological
treatment.
While anxiety disorders and trauma- and stressor-related
disorders have a nearly twofold life-time prevalence in women as
compared to men (Kessler et al., 1995, 2005; Tolin and Foa, 2006;
Kilpatrick et al., 2013; for an overview, see Cover et al., 2014),
there is increasing evidence for a role of the female sex hormone
17β-estradiol (E2) in these sex differences. Interestingly, there
is first evidence that the quality of fear extinction is related to
estrogen levels as supported by better extinction recall under high
as compared to low E2-levels.
In line with the focus of the articles assembled in this Research
Topic, we will concentrate on fear extinction and the role of stress
and stress-response mediators in animals and in humans thereby
also referring to the role of E2.
FEAR ACQUISITION AND FEAR
EXTINCTION
Fear Acquisition and the Neuronal Fear
Circuitry
The fear system can be conceptualized as an adaptive behavioral
system that allows the organism to avoid, escape or face
environmental threats (Rudy, 2014). The amygdala and its
connections play a major role in the regulation of innate fear
responses and in fear learning.
Fear acquisition involves an interplay between the basolateral
amygdala (BLA), consisting of the lateral nucleus (LA), the
basolateral and basomedial nuclei (together also referred to as
basal nuclei or basal amygdala, BA), the central nucleus (CE), and
the intercalated cell-masses (ITC), located between the BLA and
the CE (LeDoux, 2007; Pape and Paré, 2010).
The LA serves as the primary input zone of the
amygdala, receiving input from the auditory, visual, olfactory,
somatosensory, and nociceptive systems (LeDoux, 2007;
Pape and Paré, 2010; Herry and Johansen, 2014). In fear
acquisition, information about the CS and the US converges
into the LA. The LA is also a necessary site of synaptic
plasticity underlying fear learning (LeDoux, 2007; Pape
and Paré, 2010; Herry and Johansen, 2014; Tovote et al.,
2015) and a main storage site for the fear memory trace
(Pape and Paré, 2010).
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The LA projects to the basal nuclei, and to the ITC.
The ITC inhibit neurons in the CE (Royer and Paré, 2002)
and thus prevent the defensive fear responses. The basal
nuclei contain two types of neurons: so-called ‘‘fear neurons’’
and ‘‘extinction neurons’’ (Herry et al., 2008). Fear neurons
fire when fear is expressed, and they maintain excitatory
projections to neurons in the CE and in the prelimbic
cortex. Extinction neurons, on the other hand, are active
when fear has been extinguished and they project to the ITC
(Rudy, 2014).
The CE is one main output region of the amygdala with
projections to subcortical and brainstem areas. It coordinates
defensive (fear) responses including freezing and endogenous
opioid-mediated analgesia (periaqueductal gray, PAG),
and startle reflex potentiation (nucleus reticularis pontis
caudalis; Davis, 1992; Sah et al., 2003; Fanselow and Poulos,
2005; Pape and Paré, 2010). The CE is also connected to
monoamine systems in the brain, including locus coeruleus
(LC; noradrenaline, NA), dorsal/ventral striatum (dopamine,
DA), and raphe nuclei [serotonin (5-hydroxytryptamine,
5-HT)]. These neuromodulatory connections enable the
amygdala to influence the excitability of large portions of
the brain, including many areas lacking a direct connection
with the amygdala (Sah et al., 2003; Pape and Paré, 2010;
Duvarci and Paré, 2014). Finally, the CE also activates
hypothalamic nuclei producing the classical peripheral stress
response with increased sympathetic arousal, hypothalamus-
pituitary-adrenocortical (HPA) axis activation, and increased
release of glucocorticoids (GCs) and adrenaline/NA into the
bloodstream.
Thus, in the amygdala, fear expression is controlled by a fine
interplay of inhibitory and excitatory microcircuits involving the
BLA, CE, and ITC (Wolff et al., 2014; reviewed in: Duvarci
and Paré, 2014; Dejean et al., 2015). The hippocampus is
important for context fear conditioning and for encoding of
contextual information in the conditioning situation and is
thus assumed to contribute to the context-specificity of fear
responses. Accordingly, hippocampus–amygdala interactions
are regarded to be important for contextual modulation of
fear (e.g., Tovote et al., 2015). Importantly, fear expression
is also controlled by the medial prefrontal cortex (mPFC).
Neurons in the dorsal part of the mPFC [the prelimbic
cortex (PL) in rodents, and dorsal anterior cingulate cortex
(dACC) in humans and other primates] promote fear expression
(Likhtik and Paz, 2015) and both, BLA and PL/dACC activity,
are modulated by the hippocampus (Herry and Johansen,
2014).
Fear Extinction
While the fear system per se fulfills an adaptive function
it can become maladaptive and produce pathologies such
as anxiety, stressor- and trauma-related disorders (Rudy,
2014). Accordingly, conditions that improve the extinction of
conditioned fear and hinder the return of fear are important
in order to develop successful treatments of fear and anxiety
disorders.
Stages of Fear Extinction Learning and Extinction
Memory
In fear extinction, the CS is repeatedly presented without
the US and CRs decline. As already suggested by Pavlov
(1927), extinction learning does not destroy the original fear
memory, but involves new learning. The organism acquires
an inhibitory CS-no US association preventing the expression
of fear responses (Bouton, 1994, 2002; Mueller and Cahill,
2010). This is supported by the observation that conditioned
fear can easily reemerge even after successful extinction (Todd
et al., 2014). This is the case when the US alone is presented
after extinction (reinstatement), when the CS is presented in
a context different from the extinction context (contextual
renewal), or just with the passage of time (spontaneous
recovery).
Extinction covers three phases (Figure 1A): acquisition,
consolidation and retrieval of extinction (Quirk and Mueller,
2008; Mueller and Cahill, 2010). Following fear acquisition
(Figure 1B), extinction acquisition (Figure 1C) manifests
as the decline of CRs during the initial extinction training
session (Quirk and Mueller, 2008). Extinction can be
quantified by the amount and speed of this decline. During
consolidation, lasting at least several hours (Quirk and
Mueller, 2008), cellular signaling cascades progressively
stabilize the initially labile extinction memory trace into
a consolidated memory (long-term memory; Baldi and
Bucherelli, 2015). Extinction retrieval (or recall) is evident
when subsequent presentation of the CS triggers retrieval
of the extinction memory trace and only low levels of
conditioned responding occur. Thus, good extinction recall
will manifest in low CRs to the original CS (Figure 1D).
Poor extinction recall—or return of fear—is evident in
high CRs despite successful extinction. This is the case
with reinstatement (Figure 1E), renewal (Figure 1F),
and spontaneous recovery (Figure 1G). These return-
of-fear phenomena are also a challenge for anxiety
therapy, such as exposure therapies. Moreover, if the CS
is paired with the US after extinction, we usually see a
much faster reemergence of the CR (rapid reacquisition,
Figure 1H).
Of note, the timing of different phases relative to each
other is also important. For example, immediate extinction
(minutes to hours after fear acquisition) vs. delayed extinction
(24 h or more) were shown to produce different effects on
return-of-fear phenomena. While in some studies immediate
extinction produced less return of fear compared to delayed
extinction (Myers et al., 2006), this was not replicated in other
studies (Archbold et al., 2010; Golkar and Öhman, 2012). There
is even evidence that immediate extinction produces poorer
long-term fear reduction and more return of fear (Maren and
Chang, 2006; Norrholm et al., 2008; Huff et al., 2009), i.e.,
an ‘‘immediate extinction deficit’’ (for a review, see Maren,
2014).
Importantly, stress, stress-response mediators and sex
hormones may influence each of the phases of extinction
learning and memory formation differently. Therefore, we will
try to systematically review the available literature for effects on
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FIGURE 1 | (A) Illustration of basic stages of fear and extinction learning and memory including acquisition, consolidation, and retrieval. During initial pairings
between the conditioned stimulus (CS) and the unconditioned stimulus (US) during fear acquisition, responses increase over time (B). Fear memory is consolidated
thereafter. During extinction acquisition, the CS is repeatedly presented without the US and the conditioned responses (CR) decline with increasing number of CS
alone presentations (C). After consolidation, extinction recall can be tested by presenting the CS again. Good extinction recall is evident when CS-presentation
triggers retrieval of the extinction memory trace and only low levels of CR occur (D). Poor extinction recall—or return of fear—is evident in high conditioned
responses despite successful extinction. Poor extinction recall can be caused by reinstatement, i.e., presenting the aversive US (E), renewal, i.e., presenting the CS
in a new context different from the extinction context (F), or spontaneous recovery: i.e., by the passage of time (G). Despite successful extinction acquisition, new
CS-US pairing will result in faster reacquisition of the CR i.e., rapid reacquisition (H).
acquisition, consolidation, and retrieval of extinction. Where
available, we will also report effects on return-of-fear phenomena
and consider timing differences.
Presenting the CS without the US provokes a retrieval of
the original fear memory. If the number of CS presentations
is limited (1–4) this can trigger reconsolidation of the fear
memory rather than acquisition of extinction. As originally
described in the late 1960’s (Misanin et al., 1968), retrieval
temporarily destabilizes the memory trace and makes it more
susceptible to disruption. The reactivated memory is then
actively re-stabilized (Nader et al., 2000). The increased plasticity
is assumed to start about 10 min after retrieval and to last
no more than 1 h (Johnson and Casey, 2015). This opens
a brief reconsolidation-window during which pharmacological
or behavioral intervention may erase the labile memory and
prevent a return of fear. Blocking β-adrenergic receptors was
found to disrupt reconsolidation in animals (e.g., Debiec and
LeDoux, 2004, 2006; Rodriguez-Romaguera et al., 2009). There
is also good evidence that β-adrenergic blockade could present
a pharmacological tool in humans as well (Kindt et al., 2009;
Soeter and Kindt, 2010, 2012; Sevenster et al., 2013; for a review,
see Otis et al., 2015), but see also Bos et al. (2014). As a
behavioral procedure, extinction training in the reconsolidation
window was proposed and repeatedly shown to prevent the
return of fear in humans in some studies (Schiller et al., 2010;
Agren et al., 2012a) but not in others (Golkar et al., 2012;
Kindt and Soeter, 2013). In general, blocking reconsolidation
or using the reconsolidation window to modify traumatic
memories is a promising technique that might reduce fear
expression in patients with anxiety disorders or PTSD (for recent
discussions, see Lane et al., 2015; Sandrini et al., 2015). A
detailed review of reconsolidation studies is beyond the scope
of our review. In the following sections, we will focus on
effects of stress, and stress-response mediators on fear extinction.
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However, we will describe selected results from reconsolidation
studies that also include measures of extinction learning and/or
memory.
Brain Structures and Circuits Involved in Fear
Extinction
Extinction, just as fear acquisition, is distributed over a network
of structures, mainly covering the BLA, the hippocampus
and parts of the mPFC, including the PL and the more
ventral infralimbic cortex (IL) in rodents, and the dACC and
ventromedial prefrontal cortex (vmPFC) as the corresponding
structures in humans. Due to the underlying memory processes
(consolidation, retrieval, reconsolidation) the involved neural
circuits change over time (Maren and Holmes, 2016). While
the same structures are involved in fear acquisition and fear
extinction, different sets of neurons are assumed to act through
different molecular mechanisms during fear acquisition and
extinction (Maren and Holmes, 2016).
Besides fear acquisition, the amygdala is also involved in
the acquisition, consolidation and retrieval of extinction (Quirk
and Mueller, 2008). The hippocampus is the relevant site to
recall contextual information. This becomes relevant because
extinguished responses are often renewed in new contexts,
differing from the original extinction context. Moreover,
hippocampus and prefrontal cortex have a principal role in the
regulation of the retrieval of both, fear acquisition and extinction
memories (Fitzgerald et al., 2014). Concretely, the IL (in rodents)
and the vmPFC (in humans) are vital structures (Tovote et al.,
2015) for extinction recall (or fear suppression, Fitzgerald et al.,
2014). The IL mPFC integrates CS-information with contextual
information from the hippocampus to determine extinction
retrieval. Thus, in the extinction context, the IL/vmPFC inhibits
amygdala output to reduce the CR. The role of the IL specifically
for extinction retrieval is under recent debate. A recent mice
study by Do-Monte et al. (2015) showed that optogenetic
silencing of glutamatergic IL neurons during cued extinction
retrieval (1 day or 1 week after extinction acquisition) did
not abolish retrieval. However, silencing IL neurons already
during extinction acquisition impaired extinction retrieval on
the following day. This supports the conclusion that—while
relevant for the formation of extinction memory—the IL
is not necessary for the retrieval of cued fear extinction.
The one necessary structure for retrieval of cued extinction
appears to be the amygdala. Moreover, these results are one
example for recent data challenging the ‘‘canonical view’’ that
dorsal regions (PL/dACC) of mPFC regulate fear expression
and ventral regions (IL/vmPFC) fear suppression (for current
reviews, see Likhtik and Paz, 2015; Giustino and Maren,
2015).
To conclude, extinction is assumed to involve functional
changes in the network of amygdala, mPFC and hippocampus
so that extinction networks inhibit fear networks (for an elegant
review, see Tovote et al., 2015). For extinction to occur it
is critical whether the CS activates the fear neurons or the
extinction neurons in the BLA, whether ITC are activated, and
whether there is an activation of specific subsets of neurons
within the mPFC. Subsequently, when reporting effects of stress
and different stress-response mediators on extinction we will
consider data on direct effects in these brain structures where
available.
THE ROLE OF STRESS AND
STRESS-RESPONSE MEDIATORS IN FEAR
ACQUISITION AND EXTINCTION
Relevance
Acquisition of anxiety disorders and especially of PTSD can
be conceptualized as learning under severe stress. Enhanced
acquisition of trauma-relevant fear is assumed to precede the
development of PTSD (Bowers and Ressler, 2015). Accordingly,
stress-enhanced classical fear conditioning is used as an animal
model of PTSD (e.g., Rau et al., 2005). Importantly, stress and
fear responses share common neural circuits, and the neuronal
structures involved in fear acquisition and extinction are also
highly sensitive to stress effects (e.g., Lupien et al., 2009).
Studying the effects of stress or stress-response mediators
on fear acquisition and extinction thus constitutes a relevant
paradigm to examine conditions that enhance or attenuate
conditioned fear and fear extinction. This approach also aims
at mimicking: (a) the stressful nature of the situation prevailing
during the acquisition of the disorder and (b) the stressful nature
of being re-exposed to the CS afterwards, e.g., during exposure
therapy. Exposing subjects explicitly to additional stress or
stress-response mediators within a fear-conditioning paradigm
seems to be especially important in studies with humans, since
the stimuli used as US are often considerably less stressful
than US used in animal experiments. Despite the potential
relevance, human studies on the effects of acute stress on fear
extinction are still rare (for a review, see Raio and Phelps,
2015).
Features and Mediators of the Stress
Response
Stress is a process that involves multiple changes interacting
in a time-dependent manner: with respect to their onset, these
changes can be subdivided into a rapid first-wave and a (delayed)
second-wave stress response (Sapolsky et al., 2000; Rodrigues
et al., 2009). The neurotransmitters and brain areas involved in
the stress response are at least partly identical with those involved
in the fear circuitry.
The first-wave stress response (Figure 2) occurs within
seconds and involves enhanced release of (a) monoamine
neurotransmitters, i.e., of NA, DA, and 5-HT (Joëls and
Baram, 2009), (b) corticotropin-releasing hormone (CRH)
from the hypothalamus, followed by increased release of
adrenocorticotropic hormone (ACTH) from the pituitary.
Moreover, (c) there is a reduction in the release of gonadotropin-
releasing hormone from the hypothalamus, and subsequently,
a decrease in the secretion of gonadotropins, i.e., luteinizing
hormone and follicle-stimulating hormone from the pituitary.
Additional changes within the 1-min time frame (Sapolsky et al.,
2000) involve the secretion of endogenous opiates, prolactin,
glucagon, and growth hormone, as well as arginine-vasopressin
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FIGURE 2 | Features of the rapid, first wave and the delayed second wave of the stress response: onset in brain and periphery and the timing of the
activation of the mainly involved stress-response mediators (neurotransmitters, neuropeptides, hormones). The concrete time specifications of the
stress-induced changes are based on Sapolsky et al. (2000), Joëls and Baram (2009) and Hermans et al. (2014). For glucocorticoids (GCs) and sexual steroids, we
differentiate between more rapid non-genomic, and delayed genomic actions. As to the stress-induced changes in the periphery, we only refer to the following, major
changes: the rapid activation of the sympathetic nervous system and the corresponding rapid secretion of catecholamines, and to the increase in the secretion of
GCs and the decrease in the secretion of sexual steroids from the adrenal cortex. The peripheral changes feedback to the brain and the single stress-response
mediators also act on the fear extinction circuits and microcircuits (see “Contributions of specific stress mediators: insights from pharmacological manipulations,
transmitter and neuropeptide actions” and “Insights from stress-induction studies triggering the first and second wave of the stress response” Sections). When
referring to effects of single stress-response mediators on fear extinction within the text, we also take neuropeptide Y and oxytocin into account due to their role in
stress resilience and their impact on fear extinction. The bodily reactions allowing adaptation to the stress challenge are not explicitly addressed in this figure.
and renin. In the periphery, the first-wave stress response
includes a rapid increase in sympathetic tone and secretion of
adrenaline and NA from the adrenal medulla (Sapolsky et al.,
2000).
The second-wave stress response, starting after several
minutes, involves (among others) increased peripheral
secretion of GCs as a result of the activation of the
HPA-axis, and reduced secretion of gonadal steroids (i.e.,
estrogens and gestagens in the ovaries, and testosterone in
the testes; Sapolsky et al., 2000; Joëls and Baram, 2009).
This inverse action on the secretion of peripheral GCs and
gonadal steroids, and the interaction between HPA and
hypothalamus—pituitary—gonadal axis under stress is of
interest for the present review.
First- and second-wave changes not only have distinct
temporal onsets but also differ in the onset and duration of their
effects. In the brain, increased NA, DA, 5-HT, and CRH (acting
on CRH-receptor 1) usually act within seconds but their effects
subside quickly and rarely outlast the duration of the stressor; GC
concentrations in the brain only reach peak levels about 20 min
after stressor onset (Joëls and Baram, 2009; Hermans et al., 2014).
Genomic actions of GCs (and other steroids) take even longer to
manifest (Joëls and Baram, 2009). In fact, the slower genomic GC
actions were proposed to actively reverse and normalize the rapid
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effects of various first-wave stress mediators (Hermans et al.,
2014).
The brain also receives feedback from stress-induced
changes in the periphery: peripheral catecholamines which
cannot cross the blood-brain barrier, activate noradrenergic
cells via binding to adrenergic receptors of the vagus nerve.
The vagus nerve projects to the nucleus of the solitary
tract. From there, projections reach the LC (Miyashita and
Williams, 2002; Hassert et al., 2004). The amplified LC-activity
increases NA levels throughout the brain, including the BLA
(Rudy, 2014). Here, NA binds to adrenergic G-protein-coupled
receptors and initiates the cAMP signal cascade (Rudy, 2014).
Moreover, heightened central NA levels are related to an
improvement in memory storage (Rudy, 2014). GCs readily
cross the blood-brain barrier and exert negative feedback at
hypothalamic and pituitary sites to reduce CRH and ACTH
secretion (de Kloet et al., 2005). GCs also bind to higher-
affinity mineralocorticoid receptors (MRs) and lower-affinity
glucocorticoid receptors (GRs) throughout the brain, including
the amygdala, hippocampus, mPFC, and septum (Joëls and
Baram, 2009), where they can influence neural signaling and
synaptic plasticity. Thus, they can also influence memory
processes (Schwabe et al., 2012), such as those involved in fear
extinction.
Effects of Stress on Learning—Timing is
Relevant
Overview
Acknowledging the fact that fear extinction covers encoding,
consolidation and retrieval, models that studied the impact of
stress on memory in other areas—such as declarative memory in
humans and avoidance learning in rodents—should also provide
predictions for fear extinction: these models reveal that the
timing of the stressor relative to the learning task is important.
Moreover, acknowledging the complexity of the multiple stress-
response mediators over time, we will differentiate between
mediators of the first wave and those of the second wave of the
stress response.
The Role of Timing
Models derived from studies with inhibitory avoidance learning
and object recognition (in animals) and declarative memory
(in humans) suggest that stress effects on memory depend
on the temporal proximity between learning and stressor:
encoding close to the stressor (during the first wave of the
stress response) will be enhanced, but encoding and recall later
in time (during the second wave) will be suppressed (e.g.,
Schwabe et al., 2012).
In detail. Shortly after stress synergistic actions of rapid NA
and non-genomic GC (as part of the first-wave stress response)
in the BLA promote the encoding of emotionally relevant
information by enhancing synaptic excitability and long term
potentiation (Joëls et al., 2011), involving mainly glutamatergic
actions. Slower genomic GC effects (as part of the second-wave
stress response) will then enhance the consolidation of the
material learned under stress. If however, the stressor is placed
long before learning (i.e., stressor and learning are ‘‘out of sync’’),
stress should suppress the encoding of new material and impair
the retrieval of previously learnedmaterial via second-wave stress
mediators (such as genomic GCs).
There is evidence for the validity of these predictions from
animal (Roozendaal et al., 2006b; Liebmann et al., 2009; Pu et al.,
2009; Karst et al., 2010) and human studies (Henckens et al.,
2010; Zoladz et al., 2011).
In animal pharmacological fear conditioning studies,
reviewed by Rodrigues et al. (2009), evidence suggests that
the first-wave stress mediator NA plays an important role in
enhancing fear acquisition, whereas GCs as second-wave stress
mediators enhance the consolidation, but have no effect on
the acquisition of fear. The relevance of this model for fear
conditioning in humans has to be tested.
MODIFICATION OF FEAR EXTINCTION BY
STRESS-RESPONSE MEDIATORS AND
RELATED PEPTIDES
We will subsequently review the impact of stress on fear
extinction (acquisition, consolidation, and retrieval). First,
we will summarize data from pharmacological manipulations
that use drugs that affect the brain’s monoaminergic, opioid
and cannabinoid system, as well as CRH and GCs thus
specific mediators involved in the first-wave and second-wave
stress response. We here also include two peptides that
might contribute to stress resilience (see ‘‘Further mediators:
Neuropeptide Y [NPY] and Oxytocin’’ Section). Second, we
will address stress-induction studies that trigger the first and
second wave of the stress response (see ‘‘Insights from stress-
induction studies triggering the first and second wave of the
stress response’’ Section).
Modulation of fear extinction is also obtained via rapid
glutamatergic and GABAergic transmission as well as cholinergic
activity. Due to our focus on neurotransmitters and peptides that
are involved in the stress response, we do not review these effects
here. These systems are (only implicitly) included when we
refer to the glutamatergic or GABAergic mediation of extinction
processes.
Contributions of Specific Stress Mediators:
Insights from Pharmacological
Manipulations, Transmitter and
Neuropeptide Actions
Mediators of the First-Wave Stress Response
Monoamines
Overview. There is increasing evidence that the monoamines,
i.e., NA, DA, and 5-HT, which are involved in the (first-
wave) stress response (see ‘‘Features and mediators of the
stress response’’ Section), also have roles in fear extinction:
projections from noradrenergic, dopaminergic, and serotonergic
fibers reach the main structures of the fear extinction network,
the amygdala, the hippocampus, and the prefrontal cortex.
Accordingly, administering agonists and/or antagonists of the
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respective monoamine transmitter in a fear extinction setting can
elucidate the role of these monoamines. Moreover, experimental
trials administering the respective drugs and testing their impact
on extinction can serve as an experimental model for examining
effects of the combination of drug therapy and behavioral
exposure therapy (i.e., extinction learning). We will thus review
animal data, preclinical data from healthy humans and clinical
evidence from patient studies that address the therapeutic effects
of the corresponding pharmacotherapy—also as an adjunct to
cognitive behavioral therapy (CBT)—in anxiety disorders and/or
PTSD (see also the excellent reviews of Fitzgerald et al., 2014;
Bowers and Ressler, 2015; Singewald et al., 2015).
Noradrenaline (NA). NA was validated as a memory-enhancing
transmitter in many studies on emotional memory, where β-
adrenergic stimulation improvedmemory for emotional material
(e.g., Cahill et al., 1994) interacting with arousal at encoding
(Cahill and Alkire, 2003). Thus, it is reasonable that NA is also
a key modulator of extinction learning and memory. A number
of results support this:
The LC is the main localization of the cell bodies of NA-
producing cells and innervates the neural structures of the
extinction network, i.e., the amygdala, the hippocampus, and
the prefrontal cortex (Mueller and Cahill, 2010). Mechanistically,
NA acts to increase cellular excitability, and enhances synaptic
plasticity within extinction-related circuits, and fear extinction
was shown to require β-adrenergic activation in the IL-mPFC
(Mueller and Cahill, 2010). Conditioned stimuli evoke NA
release during extinction and strengthen extinction memory via
β-adrenergic signaling (Mueller and Cahill, 2010). Moreover,
GC-induced improvement of memory was shown to be mediated
by β-adrenergic signaling (Quirarte et al., 1997; Roozendaal et al.,
2002).
Animals: animal studies provide extensive evidence for a
role of central NA in the acquisition of fear extinction. Selective
forebrain NA-depletion prior to conditioning impaired fear
extinction learning but not fear acquisition (Mason and Fibiger,
1979), suggesting that NA availability is needed for successful
extinction learning. Lesions of the LC—the primer source
of forebrain NA—also impaired extinction of the nictitating
membrane reflex of the rabbit and the extinction deficit
was positively correlated with the amount of NA depletion
(McCormick and Thompson, 1982). Further support for a role
of NA in enhancing extinction learning comes from studies with
administration of the α2-receptor antagonist yohimbine, which
leads to an increased presynaptic NA release. Yohimbine before
extinction training reduced conditioned responses and enhanced
the rate of fear extinction for cue (Cain et al., 2004; Mueller et al.,
2009) and context fear conditioning (Cain et al., 2004).
A number of studies also suggest that central NAmay enhance
the consolidation and/or the recall of extinction memory: systemic
yohimbine before extinction led to a superior extinction recall for
cue (Cain et al., 2004; Morris and Bouton, 2007; Hefner et al.,
2008) and context conditioning (Cain et al., 2004). However,
yohimbine enhancement of fear extinction is context specific
and does not prevent fear renewal (Morris and Bouton, 2007).
Repeated systemic administration of the β-adrenergic agonist
isoproterenol facilitated the consolidation of fear extinction,
when administrated after each of three context exposure sessions
(Do-Monte et al., 2010). A role for NA in consolidation processes
of fear extinction is also supported by studies with central NA
administration: NA-infusions into the right BLA, immediately
(but not 3 h) after contextual fear extinction improved extinction
recall at a delayed test, but NA without extinction training had
no effect (Berlau and McGaugh, 2006). Other studies (Chai et al.,
2014) suggest that the time window for NA effects on extinction
might be different in different brain structures: Here, infusions
into the CA1 area of the dorsal hippocampus improved long term
extinction recall if NAwas administered either immediately or 12
h after contextual fear extinction (Chai et al., 2014).
An increase of NA levels in the brain can be also achieved
via electrical vagus nerve stimulation (VNS): in four experiments
Peña et al. (2013) showed that VNS during CS-exposure
accelerated extinction acquisition of both recent (24 h) and
remote (2 weeks) fear memories. Consequently, VNS paired
with the CS yielded better extinction recall compared to sham
stimulation and unpaired VNS. In a newer study (Peña et al.,
2014) VNS potentiated the IL-BLA pathway, thus contributing to
enhanced extinction. Consistently, surgical vagal deafferentiation
impaired cued fear extinction learning and was associated with
decreased levels of NA and increased GABA-levels in the ventral
PFC (Klarer et al., 2014).
For now, it is not entirely clear which adrenergic receptors
mediate the effects of NA on extinction learning and memory.
Some studies suggest central β-adrenergic receptors: repeated
(but not single) systemic administration of the β-receptor
blocker propranolol impaired both, the acquisition and the
consolidation of contextual fear extinction (Do-Monte et al.,
2010). Blocking β-adrenergic receptors in the IL PFC, impaired
cued extinction recall without affecting responding during
extinction learning (Mueller et al., 2008). Propranolol only
impaired extinction recall when administered 10 min before
extinction training, but not when administered immediately after
extinction (Mueller et al., 2008), suggesting that β-adrenergic
signaling in the IL during extinction training is needed to boost
extinction memory formation. The delayed (12 h) enhancement
of contextual extinction recall by NA in the CA1 region of
the hippocampus (Chai et al., 2014) was also dependent on
β-adrenergic receptors, activating the protein kinase A/cyclic
adenosine monophosphate response element-binding protein
(PKA/CREB) signaling pathway and increased GluR1 membrane
trafficking. This supports a role for NA in the late stages of
hippocampal memory formation. Central NA infusions also
increased the excitability of IL pyramidal cells, and the effect was
blocked by propranolol or Rp-cAMPS (a competitive antagonist
of cAMP at the PKA binding site), suggesting that NA increases
IL-excitability in a β-receptor and PKA dependent manner
(Mueller et al., 2008).
NA effects may also be co-mediated by α-adrenergic
receptors: the α1-adrenoceptor antagonist prazosin administered
systemically after each extinction session over 6 days significantly
slowed the reduction of conditioned freezing (Bernardi and
Lattal, 2010). There is also some evidence against a role for
central β-adrenergic receptors in NA-enhancement of fear
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extinction: systemic propranolol before extinction reduced CRs
during extinction, but the reduction was significant from the
first trial of extinction and there were no group differences at a
recall test (Rodriguez-Romaguera et al., 2009). This is consistent
with a reduction of fear expression (but not an enhancement
of fear extinction). In the same study (Rodriguez-Romaguera
et al., 2009), propranolol also reduced the firing rate of neurons
in the PL mPFC, a region associated with fear expression
(Sotres-Bayon et al., 2012; Courtin et al., 2014). One contextual
fear conditioning study reports no effect on extinction recall
in rats after bilateral BLA infusions of NA immediately after
training (Fiorenza et al., 2012), and an improvement after the
β-adrenoceptor antagonist timolol. In the same study (Fiorenza
et al., 2012), bilateral infusions of NA into the vmPFC (incl.
IL) impaired, whereas timolol improved contextual extinction
recall.
Humans: there are only few studies investigating NA effects
on fear extinction in humans. Healthy humans: in one study
(Bos et al., 2012) propranolol administration before extinction
impaired extinction learning in US-expectancy ratings, but
not in SCRs or fear-potentiated startle. Reboxetine (a NA
reuptake inhibitor, increasing central NA levels) administered
after extinction acquisition had no effect on the consolidation of
extinction memory (Lonsdorf et al., 2014).
Patients: in a sample of chronic PTSD-patients and
traumatized controls, propranolol had no effect on delayed
extinction recall when administered after extinction training
(Orr et al., 2006). Finally, yohimbine was tested as adjunct to
facilitate exposure therapy for anxiety disorders. Here yohimbine
(vs. placebo) significantly improved the outcome of exposure
therapy when combined with in vivo exposure for claustrophobia
(Powers et al., 2009) and social anxiety disorder (Smits et al.,
2014). Yet, in a virtual reality exposure therapy for specific
phobia (fear of flying) yohimbine had no effect (Meyerbroeker
et al., 2012).
In sum: animal data strongly suggest that NA can enhance
extinction learning and extinction memory processes. Although
NA effects were traced down to β-adrenergic signaling in
extinction-relevant structures (BLA, IL-mPFC, hippocampus),
the critical timing of effects and the relevant brain and molecular
mechanisms are still a matter of debate, as is the contribution
of other adrenergic receptor types (e.g., α1). In humans, there is
very little data showing both, positive and negative results, which
precludes clear conclusions. Given the strong animal evidence,
more human studies on NA effects in extinction are warranted.
Dopamine (DA). There is recent evidence that long-term
consolidation of extinction memory involves dopaminergic
signaling. The mPFC receives dopaminergic projections from
the ventral tegmental area and these projections contribute to
extinction via stimulating GABA-ergic cells in the amygdala
(Fitzgerald et al., 2014). This should contribute to reduced
amygdala activity and diminished expression of fear-related
behavior. The role of DA (and also NA) for extinction is
supported by animal data showing that cued fear extinction
training in rats resulted in a concomitant increase of extracellular
DA and NA in the mPFC (Hugues et al., 2007). In general,
it is expected that extinction recall is improved by DA, but
a number of procedural and pharmacological features are
relevant.
The role of DA in extinction is typically examined by systemic
administration of L-dopa (as the DA precursor), and DA agonists
or antagonists, as outlined for some important animal studies and
the available human studies.
Animals and humans: healthy individuals: Haaker et al.
(2013) used L-dopa (vs. placebo) immediately after extinction
acquisition in mice (three experiments) and humans (one
experiment). To reveal DA’s role on extinction consolidation,
return-of-fear phenomena were assessed. Mice: in a context-
conditioning paradigm (experiment 1), L-dopa (as compared
with placebo) led to lower spontaneous recovery 1 day, 7 days
and 30 days after extinction acquisition (‘‘extinction short’’,
12 CS exposures), suggesting that L-dopa improves extinction
recall. When the extinction phase was extended (‘‘extinction
long’’, 30 CS exposures, experiment 2), spontaneous recovery
(1 day and 38 days after extinction) was not diminished, but
reinstatement (day 39) was significantly lower after L-dopa.
Using cue conditioning, L-dopa (vs. placebo) resulted in less
renewal (day 8) in the original acquisition context, a higher
vmPFC-activity and lower amygdala-activity. These data further
indicate that context-dependent extinction became context-
independent via L-dopa. Humans: In the human study, cued
fear acquisition and extinction acquisition were learned on the
same day 1, followed by L-dopa (vs. placebo). One day later,
L-dopa-treated subjects showed less behavioral renewal and
a corresponding change in the neural fear circuitry with an
increase in vmPFC- and a decrease in amygdala-activity. In a very
recent human study (Haaker et al., 2015), with fear acquisition
and extinction now conducted on separate days, post-extinction
L-dopa only affected the neuronal indicators (downregulation of
amygdala activity and upregulation of vmPFC activity) but not
the behavioral level, i.e., SCR, during spontaneous recovery and
reinstatement, now 8 days after extinction.
Animals: in line with the positive role of L-dopa for extinction
memory, systemic administration of the NA- and DA-reuptake
inhibitor methylphenidate (commonly prescribed for attention
deficit hyperactivity disorder), enhanced extinction acquisition
in a contextual fear paradigm when administered immediately
before or after extinction training (Abraham et al., 2012).
Extinction was tested for another three extinction sessions on
separate days. Delivering methylphenidate 4 h after extinction
training was not successful in improving extinction retention.
Besides timing, substance type and dose have to be considered:
Using amphetamine—which inhibits the reuptake of NA and
DA non-selectively—prior to extinction, did not affect extinction
acquisition of cued fear when ultra-low doses were used
(Carmack et al., 2010), but was effective when given in higher
doses (Mueller et al., 2009).
Considering the role of DA-receptor subtype actions, there
was some initial evidence for a differential effect of D1-
vs. D2-receptors: unexpectedly, antagonizing D2-receptors (via
sulpiride), improved extinction memory whereas a D2 agonist
(i.e., quinpirole), partially blocked extinction memory compared
with the placebo controls (Ponnusamy et al., 2005). But a
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very well-controlled study (Mueller et al., 2010) meanwhile
revealed that D2-receptor signaling is even necessary for
extinction consolidation: the D2-antagonist raclopride which has
a higher specificity and is more potent than sulpiride, was given
systemically and locally (IL PFC) prior to extinction training.
D2-antagonizing impaired not only extinction acquisition (day
2) but also extinction recall in a drug-free state (day 3). The
authors even controlled for putative motor deficits provoked
by D2-antagonists by circumventing its systemic action via
direct administration into the IL PFC and found a reduced
responsiveness of IL neurons to the CS after raclopride, assessed
via single-unit recording in the IL PFC. This supports the
interpretation that D2 receptors facilitate extinction by actions
on IL PFC neurons that consolidate extinction.
Moreover, genetic differences in the dopamine
transporter genes have to be taken into account
(Agren et al., 2012b).
Interestingly, there is first evidence that estrogen is involved in
modifying the efficacy of DA activity in the vmPFC, and thereby
might affect extinction recall: D1-receptor activation in rats in a
low estrogen status was able to rescue the extinction impairment
found in these low-estrogen status rats (Rey et al., 2014). On
the other hand, the initially better extinction recall in the high-
estrogen rats diminished under the same D1-receptor agonist.
These data reveal that the natural estrogen level and DA interact
in a cycle-phase dependent manner and that a sex-hormone-
related deficit can be compensated by actions of a D1-receptor
agonist.
In sum: data support the idea that dopaminergic signaling
does improve extinction memory, but that the drug’s dose,
the temporal distance between acquisition and extinction, the
duration of the initial extinction acquisition, the temporal
distance between DA manipulation and testing, and female
estrogen status has to be taken into account. DA-agonists might
be useful as an adjunct to CBT.
Serotonin (5-hydroxytryptamine, 5-HT). Amygdala,
hippocampus, and mPFC contain 5-HT and 5-HT receptors.
Interestingly, fear conditioning per se (CS and US presentation)
was shown to induce 5-HT increase: in cued fear conditioning,
the aversive US led to an increase of extracellular 5-HT
(and also DA and glutamate) in the BLA (Yokoyama et al.,
2005). While the glutamate increase occurred only during
acquisition (day 1), 5-HT and DA also increased as a
response to the CS during extinction (day 2), although to
a smaller amount and for a shorter duration (Yokoyama
et al., 2005). Moreover, CS-exposure in fear-conditioned
rats also induced a 5-HT release in the prefrontal cortex
(Yoshioka et al., 1995). In vitro electrophysiological recording
under administration of escitalopram, a selective serotonin
reuptake inhibitor (SSRI), increased both, firing rate and bursts
of dopaminergic neurons in the mPFC (Schilström et al.,
2011).
The serotonergic system covers seven receptor families
(5-HT1–5-HT7) with a total of 16 receptor subtypes with
complex actions (Singewald et al., 2015). Research in fear
extinction mainly addresses the role of three receptor subtypes:
5-HT1a, 5-HT2 and 5-HT3. 5-HT1a and 5-HT2 receptors
have been shown to be involved in the regulation of
the excitability of the LA and the mPFC via activation
of pyramidal cells and GABAergic interneurons (Singewald
et al., 2015) and to contribute to an improvement of
extinction memory. For 5-HT3 receptors, there is some
evidence, that antagonists improve extinction (Singewald et al.,
2015).
Studies addressing the role of 5-HT on fear extinction
typically use SSRIs, SSNRIs (i.e., selective serotonin and
noradrenaline reuptake inhibitors), or amphetamine, a less
selectively-acting monoamine agonist that stimulates the release
of all three monoamines, NA, DA, and 5-HT. Again, some
exemplary animal studies and the available studies in humans are
described.
Animals: in animals, chronic administration (21 days)
of the SSRI fluoxetine (vs. placebo) after fear acquisition
but prior to extinction acquisition was effective to improve
extinction recall and to reduce return of fear (lower spontaneous
recovery; Deschaux et al., 2011). Moreover, fluoxetine given
after extinction acquisition prevented reemergence of fear
when rats experienced a stressor (weak intensity shock) as
a re-inducer of fear (Deschaux et al., 2013). Venlafaxine,
a SSNRI, administered prior to extinction acquisition also
improved extinction recall and diminished return of fear (Yang
et al., 2012), while an effect on extinction acquisition was
not found. This suggests a special impact of venlafaxine on
extinction recall, not extinction acquisition. But substance-
specific effects have to be taken into account: Chronic (22
days) administration of citalopram (which increases synaptic
availability by binding to the 5-HT transporter protein) prior
to extinction acquisition (Burghardt et al., 2013), resulted even
in an impairment of extinction acquisition, accompanied by a
downregulation of a specific subunit of the NMDA (N-methyl-
D-aspartate)-receptor (NR2B) in the lateral and basal nuclei of
the amygdala. Subchronic (9 days) administration did not induce
this impairment.
SSRIs (although not all types) could be an important adjunct
for success of exposure therapy, as evident in rats in a study
comparing the effect of fluoxetine alone (vs. placebo), extinction
training alone and the combination of both (Karpova et al.,
2011): only the combination of chronic fluoxetine treatment
(2 weeks after acquisition) and extinction training led to
less return of fear, i.e., less renewal and reinstatement. On
the neuronal level, fluoxetine increased synaptic plasticity in
the BLA and the CA1 region of the hippocampus, related
to a higher local action of brain-derived neurotrophic factor
(BDNF). Thus, the authors conclude that erasure of fear
needs ‘‘synergy’’ of pharmacological and behavioral treatment.
However, one has to keep in mind, that fluoxetine was
not only delivered prior to extinction and during extinction
acquisition, but also during extinction recall testing. Thus, from
this study, it remains unclear whether fluoxetine protection
against return-of-fear phenomena (here: renewal, reinstatement)
will also appear when being off the drug during recall
testing. So far, effects might also be explained by state-
dependency.
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There is first evidence that sex and estrogen levels interact
with the serotonergic system (Lebrón-Milad et al., 2013) in fear
extinction: Chronic (14 days), not acute, fluoxetine following
fear acquisition and preceding extinction acquisition improved
extinction acquisition and extinction recall in female, not in
male rats. In females, reduction of freezing was better when they
were in a cycle phase with low as compared to high estrogen
levels during extinction acquisition, suggesting that SSRIs might
be helpful in women under cycle conditions of low estrogen
levels where extinction recall is usually impaired (see ‘‘Sex, sex
hormones and fear extinction’’ Section).
Humans: data in humans using fear acquisition and extinction
measures is sparse so far. In healthy humans, 2 weeks of
pretreatment with the very specific SSRI escitalopram (vs.
placebo) prior to fear acquisition resulted in less SCR-responding
to the CS+, i.e., improved extinction acquisition while fear
acquisition was not modified (Bui et al., 2013).
Patients: there are several studies on the combinatory
effect of serotonergic drugs and CBT, but the effects are
validated by clinical ratings, not by fear conditioning (for
reviews, see Bowers and Ressler, 2015; Singewald et al., 2015).
So far, results are diverse, by either showing a positive
effect of CBT only, of drug only, or a beneficial effect
of the combination of both. But more data and especially
experimental designs that really address both factors, drug and
extinction (or exposure therapy) within the same study are
needed.
In sum: the effects of serotonergic drugs on fear extinction
vary with a number of factors: 5-HT receptor subtype, the actions
of the drug on the presynaptic vs. postsynaptic binding sites
(Bauer, 2015), acute vs. chronic administration, and the learning
phase that is targeted (fear acquisition vs. fear extinction).
Improvement of extinction (with extinction recall being more
affected than extinction acquisition) was obtained mainly under
chronic as compared to acute administration of 5-HT agonists
given prior to extinction.
Opioids
Endogenous opioids (including endorphins, enkephalins,
dynorphins and hemorphins; Singewald et al., 2015) are also
involved in improving extinction learning (Quirk and Mueller,
2008). An increase of endogenous opioids is among the quick
(<1 min) changes after stressor exposure (e.g., Sapolsky et al.,
2000). Thus, a stress-mediated increase of opioids might
participate in stress-mediated improvement of extinction,
mainly via stressors affecting the first-wave stress response.
Opioid receptors (µ-, κ-, and δ receptors) are expressed
in extinction-relevant brain areas, i.e., in amygdala, prefrontal
cortices, and the hippocampus (for a review, see Singewald
et al., 2015). Interestingly, ITC show a high expression of
µ-opioid receptors (Blaesse et al., 2015), further suggesting that
µ-opioid signaling might contribute to an improvement of fear
extinction. The ventrolateral PAG (vlPAG) is a main site of the
opioid actions during extinction learning, and vlPAG opioids
are assumed necessary for extinction learning to occur. A very
convincing interpretation for the involvement of opioids in
extinction learning is that omission of an expected aversive US
is rewarding (Quirk and Mueller, 2008).
Studies addressing the role of opioids for fear mainly rely on
the administration of opioid antagonists, as illustrated by a few
animal studies and studies in humans.
Animals: in rats, the administration of the µ-receptor opioid
antagonist naloxone impaired within-session extinction of fear,
while the impairment did not occur when naloxone was
administered after extinction training (McNally and Westbrook,
2003). Facilitation of fear extinction was obtained by within-
vlPAG-infusion of RB101(S), a drug that inhibits encephalin
degrading enzyme, but not when infused outside the vlPAG
(McNally, 2005).
Interestingly, there are interactions between morphine and
female sex-hormone levels in fear extinction (Perez-Torres et al.,
2015): subcutaneous morphine injections immediately after fear
acquisition (day 1) led to impaired extinction acquisition (day 2)
when female rats were in a cycle phase of low estradiol and
low progesterone (P4) level (metestrus)—as compared to females
with high levels of ovarian hormones and males. Moreover, in
the metestrus group, there was no increase of µ-opioid receptor
expression in the amygdala. Group differences were not found
when morphine was injected only at the next day (day 2),
4 h prior to extinction. Thus, in a state of low-level ovarian
hormones, morphine administered immediately after a trauma
(fear acquisition) might unintendedly even increase the recall of
fear.
Humans: in humans, extinction deficits were found
under genetic variations of opioid-receptor expression:
subjects with a single nucleotide polymorphism in the gene
encoding prodynorphin (acting on the κ-opioid receptor),
exhibited impaired fear extinction and reduced functional
connectivity between amygdala and vmPFC (Bilkei-Gorzo et al.,
2012).
Patients: Arntz et al. (1993) examined the effect of the
blockade of opioid transmission via the opioid antagonist
naltrexone in 48 spider-phobics that underwent a 2 h exposure
session given low-dose, or high-dose naltrexone, or placebo.
Behavioral avoidance measures, emotional, physiological and
cognitive measures were assessed prior to, during, and one week
after exposure. Opioid blockade resulted in a dose-related relapse
of behavioral avoidance while the other measures did not differ.
Morphine was also found to be important for the secondary
prevention of PTSD (for a review, see Bowers and Ressler,
2015): children traumatized by acute burns developed less PTSD
symptoms when given morphine post trauma (e.g., Stoddard
et al., 2009). Moreover, the morphine dose in the 48 h after
trauma was one of the predictors of PTSD severity 3 months after
the trauma: patients with the later diagnosis PTSD had obtained
less morphine in the aftermath of the traumatic injury (Bryant
et al., 2009). Based on the data from Perez-Torres et al. (2015),
estradiol levels should be taken into account and be validated for
PTSD immediately after trauma exposure.
In sum: data converge to reveal an impairment of extinction
via opioid antagonists and evidence for an improvement of
symptoms in trauma-related disorders when morphine is given
after the trauma. But the exact timing of opiate administration
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and/or of opioid action as well as the cycle phase in females has
to be taken into account. With regard to its pain-inducing effects,
the cold pressor test (CPT) used as a means to induce acute stress
in fear conditioning studies in humans (see ‘‘Insights from stress-
induction studies triggering the first and second wave of the
stress response’’ Section), is a very interesting candidate because
it does not only provoke a rapid increase of NA, but should also
affect the opioid system.
Cannabinoids
Cannabinoid-type 1 (CB1) receptors have a high density in
amygdala and hippocampus. The endogenous production of
cannabinoids via the endocannabinoid system is regarded to be
relevant for emotional and cognitive processing of threatening
stimuli (Bitencourt et al., 2008). As recently reviewed (Quirk
and Mueller, 2008; Fitzgerald et al., 2015; Papini et al., 2015),
there is evidence for a facilitating role of endocannabinoid
signaling in extinction learning via the CB1-receptor. A role of
endocannabinoids (eCBs) for improving fear extinction is also
supported by increased levels of eCBs in the BLA after extinction
training (Marsicano et al., 2002). Moreover, eCBs and CB1-
receptors were shown to induce depression of GABA-mediated
inhibitory currents (Marsicano et al., 2002).
Importantly, stress and GCs influence eCBs levels (reviewed
inMaren and Holmes, 2016): stress and GCs increase eCBs in the
BLA, and eCBs act on brain GCs and on the HPA axis (Hill et al.,
2010). eCBs were also shown to contribute to an NA-induced
improvement of extinction memory by the following GC-related
actions: An increase of GCs (induced in an emotionally aversive
situation) at the brain GRs was shown to activate pathways that
induce eCB synthesis. eCBs then inhibit GABAergic neurons,
and thus disinhibit NA release (Atsak et al., 2012)—or in other
words, increase NA recruitment. Thus, eCBs might contribute
to an NA-mediated improvement of extinction memory after
preceding GC increase.
The role of eCBs in fear extinction is typically examined using
transgenic mice lacking the CB1-receptors, or by administering
CB1 agonists and antagonists or inhibitors of enzymes that are
involved in the reuptake or breakdown of eCBs (for a review, see
Papini et al., 2015).
Animals:CB1-knockout mice show normal acquisition of fear
conditioning (freezing behavior), but impairment of extinction
acquisition and extinction retention suggesting a role of CB1
for extinction, not acquisition of fear (Marsicano et al., 2002).
Accordingly, blockade of the CB1 receptor was shown to impair
extinction learning, while administration of CB1 agonists and CB
reuptake inhibitors improved extinction in animals in a number
of studies as specified below:
As to CB1-antagonists, SR141716A (Marsicano et al.,
2002) impaired extinction acquisition and recall, but not fear
acquisition. Similarly, the CB1-antagonist rimonabant dose-
dependently reduced extinction learning of fear-potentiated
startle (Chhatwal et al., 2005). Correspondingly, CB1 agonists
improved extinction recall: the CB1-agonist phytocannabinoid
cannabidiol (Bitencourt et al., 2008), and AM404, an eCB
reuptake inhibitor injected prior to extinction acquisition,
facilitated extinction recall (Chhatwal et al., 2005; Bitencourt
et al., 2008) and reduced reinstatement (Chhatwal et al., 2005).
AM-3506 (preventing the degradation of anandamide), given
either systemically or infused locally into the amygdala prior to
extinction, also resulted in better extinction recall, while it had no
effect in the absence of extinction training (Gunduz-Cinar et al.,
2013).
Evidence for the local action of eCB in fear extinction circuitry
is further supported by results that pre-extinction infusions of CB
antagonists into fear-relevant brain areas impaired extinction,
while pre-extinction infusion of agonists improved extinction
recall, but results are still mixed (Papini et al., 2015).
Humans: Klumpers et al. (2012) compared effects of
∆-9-tetrahydro-cannabinol (THC) vs. placebo administered
prior to extinction acquisition in healthy humans: they found an
improvement of extinction acquisition (lower number of CRs) in
SCRs, but not in fear-potentiated startle; the improvement did no
longer remain in the retention test. But effects on extinction recall
were found in other studies (Das et al., 2013; Rabinak et al., 2013,
2014): when administering cannabidiol, a CB1-receptor agonist
and non-psychoactive component of cannabis (vs. placebo),
either prior to or following extinction acquisition (Das et al.,
2013), extinction acquisition was not affected, but extinction
recall improved (manifesting in expectancy ratings) when
cannabidiol had been administered after extinction acquisition,
thus suggesting an effect on consolidation of extinction memory.
Less reinstatement (trend level in the SCRs) was found after both
time-points of eCB-administration, prior and after extinction
training. Longer-lasting effects on extinction recall (day 3) were
also observed after a single oral dose of the synthetic form of
∆-9-THC, dronabinol (vs. placebo) administered prior to (not
after) the extinction acquisition (day 2; Rabinak et al., 2013). In a
similar study, another synthetic THC,marinol, now did not affect
SCR during extinction recall (day 3) but led to an increase of
vmPFC and hippocampus activation to a previously extinguished
CS+ in a differential conditioning paradigm (Rabinak et al.,
2014).
Probably, genetic markers might help to reconcile the partly
inconsistent results: healthy humans with reduced CB1-receptor
expression showed impaired fear extinction in a virtual reality
paradigm (Heitland et al., 2012).
Patients: the contribution of impaired eCB-signaling in
patients with PTSD is also a matter of debate and is elegantly
reviewed by Papini et al. (2015). In a recent study using positron
emission tomography (PET), patients with PTSD were shown to
have a ∼50% reduction of the peripheral eCB anandamide and
a ∼20% higher availability (upregulation) of CB1 receptors in
amygdala, hippocampus, and the cortico-striatal network than
healthy controls. This pattern was more pronounced in women
(Neumeister et al., 2013). Thus, a lower anandamide-tone might
contribute to symptoms of PTSD and might lead to impaired
extinction.
In sum: there is evidence for a positive role of eCBs
for enhancing extinction recall and—correspondingly—for an
impairment of extinction recall when eCB signaling is impaired.
Moreover, acute, not chronic drug administration appears to
be helpful to improve extinction recall. Further, more studies
have to be conducted to find out how low eCB levels and
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upregulation of brain CB1-receptors might contribute to PTSD.
The interaction between eCBs and stress is very interesting in the
context of this review.
Corticotropin releasing hormone (CRH)
CRH neurons and CRH receptors are not only available in stress-
responsive areas, but also in areas of the fear circuitry, i.e., in the
BLA and the CE of the amygdala (Gafford and Ressler, 2015).
Animals: animal data show that intra-BLA infusion of
CRH and of CRH binding protein (leading to an increase of
endogenous CRH levels) prior to fear extinction impaired
extinction recall while not affecting extinction acquisition.
Correspondingly, a CRH-receptor antagonist improved
extinction recall (Abiri et al., 2014). Similarly, in a transgenic
mouse model missing the GABA(A)α1 subunit of the CRH
neuron, CRH messenger RNA (mRNA) was elevated in the
amygdala, the BNST and the hypothalamic paraventricular
nucleus. The transgenic mice showed impaired extinction of
conditioned fear and higher plasma cortisol levels. Deficits were
successfully treated by systemic as well as local (BNST) infusion
of a CRH-antagonist (Gafford et al., 2012).
Humans: in patients with PTSD, a hyperarousal of CRH
pathways is described (Gafford and Ressler, 2015). Currently,
a multicenter randomized controlled trial is in progress testing
the effects of a CRH-type 1 receptor antagonist (GSK561679) in
women with PTSD (Dunlop et al., 2014). Women will receive
either 6 weeks drug treatment or placebo, and among a large
number of dependent variables, fear acquisition and extinction
will be assessed.
Further Mediators: Neuropeptide Y (NPY) and
Oxytocin
Recent data also provide a role for NPY and oxytocin in
extinction memory. Both peptides are known for being involved
in stress resilience.
Neuropeptide Y. High concentrations of NPY are found in
the cortex, amygdala, the hippocampus and the PAG, and in
hypothalamic regions. NPY acts through six receptor subtypes,
(Y1 to Y6), with Y1, Y2, Y4 and Y5 as the functional subtypes
in the human brain (Bowers et al., 2012). NPY is co-localized
with GABA within the BLA (Bowers et al., 2012). Since NPY also
contributes to resilience after stress (Feder et al., 2009; McGuire
et al., 2011) it might have an interesting role in regulating fear
acquisition and extinction under stressful conditions.
Animals: intracerebroventricular NPY resulted in an
improvement of extinction acquisition in fear-potentiated
startle (Gutman et al., 2008), while mice lacking both, Y1 and
Y2 receptors, showed accelerated acquisition of conditioned
fear, excessive recall of conditioned fear and impaired fear
extinction (acquisition and recall; Verma et al., 2012). Over-
expression of the selective Y2-agonist NPY3–36 in the CE of
the amygdala resulted in improved extinction acquisition in
cued (not contextual) fear conditioning and minor return
of fear (less spontaneous recovery and reinstatement), while
local destruction of Y2-receptors impaired extinction memory
(Verma et al., 2015).
Humans: we are not aware of data addressing NPY in fear
extinction studies with healthy humans. Indirect evidence comes
from data revealing that subjects with genotypes that predispose
to have low NPY levels showed a higher responsiveness to
aversive stimuli (negative words) in the mPFC and rostral ACC
than those with intermediate or high expression (Mickey et al.,
2011). Further, patients with PTSD (Rasmusson et al., 2000) were
shown to have lower NPY baseline levels than healthy controls.
In sum: first animal data converge that NPY might help
to improve fear extinction acquisition and recall. The results
in humans only come from quasi-experimental and correlative
studies in patients, but provide a first hint that high NPY levels
might also be relevant for improving fear extinction in humans.
Oxytocin. Among other locations, oxytocin receptors are also
located in the amygdala and the dorsal and ventral hippocampus.
Moreover, due to its regulatory effects on the HPA-axis
activation, oxytocin is an interesting neuropeptide for fear
extinction under stress.
Animals: oxytocin was shown to inhibit excitatory output to
brain-stem fear-expression centers when injected into the CE of
the amygdala, here interacting with vasopressin (Huber et al.,
2005). It also resulted in higher heart rate variability (as an
indicator of a more vagal tone of heart rate modulation) during
extinction acquisition and reduced expression of fear (Viviani
et al., 2011). Thus, one should expect oxytocin to improve
extinction recall, but the time-point of administration appears to
be very important.
Intracerebroventricular injection of synthetic oxytocin prior
to fear acquisition did not affect fear acquisition but facilitated
extinction acquisition and retrieval, an effect that was abolished
by an oxytocin-receptor antagonist. Interestingly, oxytocin
given prior to extinction acquisition instead impaired extinction
learning; this effect was again abolished by blockade of the
oxytocin receptor (Toth et al., 2012). This suggests, that oxytocin
needs to be already administered prior to fear acquisition, and
that caution is necessary when considering the use of oxytocin
after the acquisition of a trauma. Recently, oxytocin was shown
to reduce reconsolidation of fear memories in rats after a single
systemic injection after the reactivation of fear (Hou et al., 2015).
Humans: there is some evidence for facilitating effects of
pre-extinction oxytocin on subsequent extinction acquisition
(Eckstein et al., 2015) and fear extinction recall (Acheson et al.,
2013) while a pilot clinical study using oxytocin prior to an
exposure session in spider phobia revealed even debilitating
effects (Acheson et al., 2015).
In a fear-potentiated startle paradigm (Acheson et al., 2013),
subjects received either intranasal oxytocin or placebo after
fear acquisition, followed by extinction acquisition (45 min
after substance administration) on day 1, and extinction recall
on day 2 (24 h later). While the oxytocin group showed
higher startle magnitudes in the early extinction trials, both
groups manifested reduced responding by the end of extinction
acquisition on day 1. On day 2, extinction recall was better after
previous oxytocin treatment, suggesting an oxytocin-induced
enhancement of extinction consolidation. Eckstein et al. (2015)
only addressed fear acquisition and extinction acquisition on
Frontiers in Behavioral Neuroscience | www.frontiersin.org 13 January 2016 | Volume 9 | Article 359
Stockhorst and Antov Fear Extinction, Stress and Estradiol
a single day in a differential conditioning paradigm. They
measured SCR and blood oxygen dependent (BOLD) signal
from functional magnetic resonance imaging (fMRI). Intranasal
oxytocin (vs. placebo) was again given after fear acquisition. In
the early trials of extinction acquisition, oxytocin (vs. placebo)
even induced a higher SCR, but also a higher activity in
the right PFC. By the end of extinction, oxytocin resulted in
lower SCRs. Moreover, oxytocin led to an unspecific inhibition
(affecting CS+ and CS−) in amygdalar responses in early and
late extinction acquisition. Extinction recall was not assessed
here.
Patients: in a recent study, intranasal oxytocin (vs. placebo)
was delivered as a pretreatment immediately prior to a
single-session exposure treatment for spider phobia (Acheson
et al., 2015). Dependent measures covered self-report of
spider-phobia symptoms, phobic avoidance behavior, and
trust into treatment (treatment creditability and therapeutic
alliance). Follow-up was located 1 week and 1 month after
exposure. Oxytocin- as compared to placebo-treated subjects
manifested even higher clinical ratings of fear symptoms,
higher avoidance behavior (as rated by clinicians) and less
confidence into the treatment and a trend for less therapeutic
alliance.
In sum: data suggest that some caution is necessary when
delivering oxytocin prior to extinction (or prior to exposure
therapy). There is evidence for both, extinction-improving and
extinction-debilitating effects. More data are needed to find out
whether oxytocinmight especially affect extinction consolidation
(and not extinction acquisition) and how oxytocin acts on
extinction neurocircuits.
Second-Wave Mediators
GCs, extinction learning and the role of circadian
variation/rhythm
There is a substantial amount of evidence suggesting that
GCs have a positive influence on fear extinction learning
and memory. Systemic (Cai et al., 2006; Yang et al., 2006,
2007; Brinks et al., 2009; Blundell et al., 2011) and intra-
amygdala administration (Yang et al., 2006) of GC agonists
(e.g., corticosterone, dexamethasone) facilitates fear extinction
memory when given prior to or directly after extinction training.
In contrast, GR antagonists or the GC-synthesis inhibitor
metyrapone impair extinction memory when administered
systemically (Barrett and Gonzalez-Lima, 2004; Yang et al.,
2006, 2007; Blundell et al., 2011) or into the amygdala (Yang
et al., 2006). Importantly, the facilitating effect of GR-agonist
dexamethasone was blocked by intra-amygdala infusion of
the GR-antagonist mifepristone (Yang et al., 2006), suggesting
that GRs in the amygdala are mediating the enhancement of
extinction. Comparing post-reactivation administration of GC or
a β-blocker (Abrari et al., 2008) suggest that GCs affect extinction
memory per se, without compromising reconsolidation. Yet,
GCs may have opposite effects on fear extinction mediated by
different actions on GRs and MRs. Systemic administration
of a low-dose GR agonist (dexamethasone) or administration
of the MR-antagonist spironolactone both enhanced contextual
fear extinction (Ninomiya et al., 2010), whereas MR-agonist
fludrocortisone impaired extinction. High-dose dexamethasone
or the GR-antagonist mifepristone had no effect (Ninomiya et al.,
2010).
Importantly, data also suggest, that GRs can alleviate
stress-induced extinction impairments. In the immobilization
stress model of PTSD stress exposure impairs fear extinction
a week later (Sawamura et al., 2015). However, systemic
GR-agonist dexamethasone 4 h before extinction rescued
extinction deficits in previously stressed rats and improved
extinction acquisition and recall (Sawamura et al., 2015).
Conversely, in the single prolonged stress (SPS) model,
GC-synthesis inhibitor metyrapone exacerbated SPS-
induced extinction recall deficits (Keller et al., 2015b).
GR-signaling in the hippocampus has also been recently
implicated to be one of the pathways mediating the
enhancement of contextual fear extinction by novelty (Liu
et al., 2015).
In sum, animal studies show that endogenous GCs play
an important part in successful fear extinction and extinction
memory, and GC administration can improve extinction. These
effects are probably mediated through central GRs, especially in
the amygdala and hippocampus.
Humans: studies addressing the effects of GC administration
on fear extinction in humans are scarce and results are
mixed. While there are reports that hydrocortisone (30 mg)
administration impaired extinction learning in men (SCR and
BOLD; Merz et al., 2014b), other studies find an enhancement in
(BOLD-signal) differentiation during extinction in women using
hormonal contraceptives (Tabbert et al., 2010). Here however
(Tabbert et al., 2010), hydrocortisone increased responses to
the CS− (never paired with the US) vs. CS+ (previously paired
with the US) which is hard to interpret. Another study found
no effect of the same dose of hydrocortisone (30 mg) in
men and free-cycling women (Merz et al., 2012a). On the
other hand, clinical studies have shown enhanced outcome
of exposure therapy, when GCs were administered prior to
exposure training for specific phobias (Soravia et al., 2006,
2014; de Quervain et al., 2011). For PTSD, combining exposure
techniques with GCs led to lower avoidance/numbing symptoms
compared to placebo 1 week after intervention, but the effects
did not last at a 1 month follow-up (Surís et al., 2010). Low-
dose cortisol alone has also shown some promising results
in a pilot study with 3 PTSD-patients (Aerni et al., 2004).
Endogenous levels of GCs show a marked diurnal variation
with a peak in the early morning after awakening. This
peak has been linked to enhanced extinction/extinction recall
(Pace-Schott et al., 2013) and a better outcome of exposure
therapy in humans in the morning (Lass-Hennemann and
Michael, 2014). However, only one study shows a circadian
effect with a direct positive association between endogenous
GC levels and exposure therapy outcome (Meuret et al.,
2015).
To summarize: in line with animal studies, in humans,
GC administration combined with exposure therapy has
shown some promise to yield a better therapy outcome.
Similar conclusions can be drawn from diurnal effects
in humans. Both lines of evidence indirectly point to
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a possible enhancement of fear extinction by GCs in
humans, as repeatedly shown in rodents. However, the few
studies with GC administration directly examining fear
extinction in healthy volunteers cannot back up clinical
trials yet.
Insights from Stress-Induction Studies
Triggering the First and Second Wave of
the Stress Response
So far, we reported effects of single mediators of the
stress response from pharmacological manipulations. This is
important, but no substitute for experimentally induced stress.
As stress responses are typically defined by the interplay of
multiple mediators (Joëls and Baram, 2009), and as GC effects
in the amygdala were shown to depend on arousal-induced
NA-signaling (Roozendaal et al., 2006a), single pharmacological
manipulations might be insufficient. Despite the potential
relevance for clinical settings, especially human studies on the
effects of acute stress on fear extinction are still rare (for a review,
see Raio and Phelps, 2015). Below, we review animal and human
stress-induction studies on fear extinction focusing broadly on
acute stress effects. Effects of chronic stress on fear extinction
and effects of stress during pre- and postnatal development on
extinction are beyond the scope of this review.
Animals: the field has focused on designs where extinction
follows one to several days after stress, thus reflecting
longer lasting effects of second-wave mediators. A number of
procedures have been suggested to model features of PTSD in
laboratory animals (e.g., Rau et al., 2005). The SPS model is
especially well studied with fear extinction. SPS comprises 2 h
restraint stress, 20 min of forced swim stress, and exposure to
ether until general anesthesia (Yamamoto et al., 2008). When
applied 7 days before fear acquisition and extinction the SPS was
repeatedly shown to impair extinction learning and especially
extinction recall while leaving fear acquisition intact (Yamamoto
et al., 2008, 2009; Knox et al., 2012a,b; Ganon-Elazar and
Akirav, 2013; Matsumoto et al., 2013). The delayed effects of
SPS on fear extinction were linked to enhanced GR-expression
in the hippocampus and PFC (Knox et al., 2012b) and to
upregulation of NMDA-receptor mRNA in the hippocampus
(Yamamoto et al., 2008; Matsumoto et al., 2013). However,
no impairment of extinction was found after a shorter time
interval between stress and learning (Knox et al., 2012a), or after
reducing stressor intensity by omitting either one of the SPS
components (Knox et al., 2012b). In a different model, placing
repeated forced swim stress (10 min/day for 3 days) 24 h before
cued fear acquisition and 48 h before extinction also impaired
extinction learning (but not fear acquisition) and produced
dendritic retraction in IL neurons in the PFC (Izquierdo et al.,
2006).
Behavior during/after extinction can be seen as the result
of a competition between the original fear memory and the
new inhibitory extinction memory. Therefore, placing stress
before fear acquisition makes precise inferences about stress
effects on extinction difficult, as stress could have modified the
original fear memory. However, there is also evidence that stress
impairs fear extinction even when animals are stressed after
fear acquisition: 30-min of elevated platform stress 24 h before
extinction impaired extinction learning and was associated with
changes in BLA morphology, including dendritic retraction and
debranching but also increased spine density (Akirav et al., 2009;
Maroun et al., 2013).
In some cases, stress exposure can also facilitate fear
extinction. A single exposure to 3 h of immobilization stress
14 days (but not 2 days) before contextual fear acquisition and
extinction significantly improved extinction recall (Kirby et al.,
2013). The stress effects were linked to increased neurogenesis in
the dorsal hippocampus and seem to be mediated through stress-
induced GCs activating basic fibroblast growth factor (FGF2;
Kirby et al., 2013).
In sum: the combined evidence suggests that stress impairs the
consolidation/recall of fear extinction. The impairment requires
time (>24 h) and is associated with structural changes in
extinction-relevant structures including dendritic morphology,
and receptor density. Stress-induced extinction impairments
seem more likely with severe, prolonged and high-intensity
stressors.
Humans: here, we group studies by (a) the type of stressor and
its validity for triggering the first- vs. second-wave stress response
and (b) by considering the timing of the stressor relative to
stages of extinctionmemory formation (encoding, consolidation,
recall). Stress placed already before fear acquisition will give a
better comparison to the animal studies above. Stress placed
after fear acquisition but before extinction gives insights into
effects on encoding. Stress after extinction learning informs us
about consolidation effects. Finally, stress before extinction recall
captures influences on recall independent from learning and
consolidation.
Although considerably fewer in number, human studies also
suggest that stress placed before fear acquisition (and thus also
extinction) may impair fear extinction. We have recently shown
(Antov et al., 2013), that inducing the first-wave stress response
immediately before fear acquisition impaired extinction even
without a second-wave GC-increase. We used the CPT, where
participants immerse their hand into ice-cold water for a max
of 3 min and found increased extinction resistance compared
to control, probably due to a strengthening of the original fear
memory. Yet, a psychosocial stressor inducing significant GC-
increases had no effects on conditioning (Antov et al., 2013). In
contrast, a psychosocial stressor 70 min before fear acquisition
impaired extinction (Jackson et al., 2006), and uncontrollable
shocks 7 days before fear acquisition reduced extinction recall
(Hartley et al., 2014).
Placing first-wave stress (CPT) after acquisition but
immediately before extinction training facilitated extinction
acquisition and extinction recall without second-wave GC-
increases (Antov et al., 2015). Bentz et al. (2013) also placed
the CPT prior to extinction training: they found that CPT
impaired recall of the original fear memory (measured in
subjective US expectancy) in men but not in women. As
discussed by the authors (Bentz et al., 2013), this study has
some important limitations precluding inferences about stress
effects on extinction: (1) there was no evidence for fear learning
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(or extinction) in physiological conditioning measures (SCR,
heart rate), (2) there was also no extinction learning in any
measure. A variant of the CPT including social evaluation
(SECPT, Schwabe et al., 2008), also inducing GC-increases,
placed after fear extinction impaired extinction recall 24 h later,
especially when tested in the acquisition context (Hamacher-
Dang et al., 2015). Finally, two studies suggest that stress also
affects the retrieval of fear extinction: CPT associated with
GC-increases 15 min before delayed extinction recall (Raio et al.,
2014) significantly impaired recall performance. Conversely, the
SECPT placed 20 min prior to extinction recall and 24 h after
extinction learning, reduced contextual fear renewal (Merz et al.,
2014a), probably indicative of enhanced extinction recall.
In sum: the few available human studies yield mixed results,
but there is some evidence that first-wave stress before extinction
learning improves extinction acquisition and recall whereas
second-wave stress before recall testing impairs extinction recall.
SEX, SEX HORMONES AND FEAR
EXTINCTION UNDER STRESS
Sex, Sex Hormones and Fear Extinction
Compared to men, the prevalence of anxiety (Kessler et al.,
2005; Somers et al., 2006; Eaton et al., 2012) and trauma- and
stressor-related disorders (Kessler et al., 1995; Tolin and Foa,
2006; Kilpatrick et al., 2013; Zoladz and Diamond, 2013) is up
to two times higher in women.
Levels of circulating gonadal hormones (mainly estrogens)
are regarded to contribute to these sex differences in
psychopathology (Lebron-Milad and Milad, 2012; Cover
et al., 2014).
Estrogens are a class of steroidal sex hormones that include
estrone (E1), estradiol (E2), estriol (E3), and estetrol (E4). E2 is
produced by the ovaries and (to a smaller amount) by the adrenal
cortex, and by the testes in men by conversion from testosterone
via the enzyme aromatase or by conversion of androstenedione
to E1 and conversion of E1 to E2. E1 is the dominant estrogen
during menopause and E3 and E4 dominate during pregnancy.
E2 is the predominating estrogen in non-pregnant women in
their reproductive years when E2-levels are considerably higher
in women than in men. In humans, an idealized menstrual
cycle lasts 28 days and includes the following phases of different
concentrations of E2 and P4 (Becker et al., 2005): E2 and P4 are
low during the early follicular phase (approx. cycle days 1–8).
During the late follicular phase, P4 remains low, while E2 rises to
reach its peak immediately before ovulation (midcycle, approx.
days 13–14). Peak P4 levels are only reached during the mid-
luteal phase, where there is also a second less prominent peak
in E2. In rodents, the estrous cycle lasts 4–5 days and covers four
phases: metestrus (low E2 and low P4), diestrus (moderate P4 and
low E2), proestrus (high E2 and high P4), and estrus (low E2 and
low P4; Maeng and Milad, 2015).
E2 exerts its effects via two types of steroidal estrogen
receptors located in the cell nucleus or the cytoplasm: estrogen
receptor alpha (ERα) and beta (ERβ) which are both widely
distributed across the brain (Gillies and McArthur, 2010).
ERα are broadly distributed across cortical and subcortical
structures including hippocampus, amygdala, hypothalamus,
and brain stem, whereas ERβ distribution is less wide-spread with
medium to high ERβ density throughout the cortex including
the vmPFC, high density in the hippocampus, and in some
hypothalamic nuclei (Gillies and McArthur, 2010; Cover et al.,
2014). Importantly, ERs are well expressed in brain regions
critical for fear acquisition and extinction including amygdala
subnuclei, hippocampus and vmPFC (Shughrue et al., 1997;
Österlund et al., 1998, 2000; Zhang et al., 2002; Weiser et al.,
2008).
Neuroimaging studies reveal that circulating levels of E2
in women affect the reactivity of brain structures involved in
both, stress and fear acquisition and extinction. Specifically,
women scanned during the midcycle phase (peak E2, but low P4)
exhibited significantly less responses to high arousing, aversive
visual stimuli (International Affective Picture System, IAPS; Lang
et al., 2008) in the amygdala, ACC, orbitofrontal cortex, mPFC,
hippocampus, PAG, and several hypothalamic nuclei compared
to both, men and women tested during the early follicular phase
(low E2 and low P4; Goldstein et al., 2005, 2010).
Estrogens were shown to be especially important in fear
extinction: in an elegant series of experiments in rats, Chang et al.
(2009) found faster extinction of contextual fear conditioning
in female than male rats, especially when in the high E2-
phase of the estrous cycle (proestrus). The authors also
observed enhanced extinction after systemic and central E2-
administration to ovariectomized animals and traced the effects
back to hippocampal ERβ by using selective ERα/ERβ agonists.
There is accumulating evidence for the role of E2 especially
for extinction recall in both laboratory animals and healthy
humans: low E2-levels were shown to impair and high E2-
levels to enhance extinction recall, typically tested 24 h after
extinction training (Milad et al., 2006, 2009a, 2010; Zeidan
et al., 2011; Graham and Milad, 2013). Studies also include
data on low-level estrogen under contraceptives (Graham and
Milad, 2013). Moreover, in mice both, high endogenous E2
and activation of ERβ, enhanced glutamatergic transmission and
synaptic plasticity in the IL mPFC (Galvin and Ninan, 2014),
a structure associated with consolidation and recall of extinction.
Interestingly, inhibition of estradiol synthesis by an aromatase
inhibitor (fadrozole) in male rats, significantly impaired their
extinction recall (Graham and Milad, 2014). Adequate controls
(such as delivering a single dose of E2 after previous aromatase
inhibitor) gave first evidence that fear extinction in males may
also depend on acute effects of estrogen synthesized de novo and
acting presumably via non-genomic mechanisms. In contrast to
the majority of studies supporting an enhancement of extinction
by high E2-levels, there is recent evidence for the opposite effect,
i.e., enhanced fear memory and impaired extinction memory
under high E2-levels (McDermott et al., 2015). But this study did
not assess female rats under natural E2 conditions but studied
E2 replacement in female ovariectomized mice (vs. mice after
sham surgery) instead. Chronic high-dose, not low-dose, E2
administration in pre-puberty (4 weeks) and in adult age (10
weeks), impaired extinction but only in contextual, not cued,
fear conditioning. This suggests an adverse effect of chronic high
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E2-levels for hippocampus-mediated fear inhibition. Anyway,
we have to take into account, that chronic high E2 actions
after ovariectomy do not necessarily reflect ‘‘normal’’ E2 actions
within the brain and periphery.
Addressing brain correlates during fear extinction and
considering different E2-levels in humans revealed that women
using oral contraceptives (having suppressed E2-levels) showed
higher differential BOLD responses to the CS+ (previously paired
with the US) during fear extinction compared tomen andwomen
in the luteal phase of the menstrual cycle (high P4, medium-high
E2) in the amygdala, ACC, and vmPFC (Merz et al., 2012a). This
is in line with impaired extinction when E2-levels are low. The
study also included administering cortisol vs. placebo but this did
not affect the results (see also ‘‘Second-wave mediators’’ Section).
Accordingly, a recent study examining women during the early
follicular and luteal phases of the menstrual cycle (Wegerer et al.,
2014) reported that low E2 but not P4 was associated with poorer
extinction and with higher intrusive memories.
Patients: with PTSD exhibit marked fear extinction deficits
as compared to healthy controls (Milad et al., 2009b; Inslicht
et al., 2013) or trauma-exposed and non-trauma-exposed
healthy controls (Milad et al., 2009b). Interestingly, fear
inhibition/extinction deficits have been linked to low levels
of E2 in both female PTSD-patients (Glover et al., 2012) as
well as in healthy and traumatized women (Glover et al.,
2013). A recent study by Shvil et al. (2014), addressing sex
differences in trauma-exposed healthy controls vs. PTSD-
patients, found impaired extinction recall (higher SCRs
to the extinguished CS+) and higher activity in the left
rostral dACC in men as compared to women within the
PTSD group, but not in trauma-exposed healthy controls.
The result also suggests that interventions improving
fear extinction are highly important in male patients with
PTSD.
In sum: the available data suggest an important role of E2
for fear extinction with high E2-levels enhancing extinction
acquisition and especially extinction recall (with most of the
studies comparing different E2-levels within females). The
assessment of E2-levels should be thus included in fear extinction
studies. Comparing women in different cycle phases and
under different natural E2-levels is only a quasi-experimental
approach. Thus, experimental studies would be important with
experimental variation of sex-hormone levels.
Interaction of Stress and Sex Hormones in
Fear Extinction
Although trauma- and stressor-related disorders are associated
with deficits in fear extinction, we still do not know much about
the effects of acute stress on fear acquisition and extinction in
healthy humans (Raio and Phelps, 2015). Importantly, animal
data suggests that stress effects on fear conditioning are sex
specific (Dalla and Shors, 2009). For example, in ovariectomized
female rats an injection of E2 (45 µg/kg) was able to alleviate
conditioned fear responses after SPS (Mirshekar et al., 2013),
suggesting an E2 × stress interaction. In intact females (as
compared to males), SPS did not impair extinction learning
or recall, regardless of estrous cycle phase (Keller et al.,
2015a).
In humans, Zorawski et al. (2005) found that the level of post-
acquisition GCs was positively correlated with fear acquisition
performance (SCR) in men, but not in women. This was later
replicated (Zorawski et al., 2006) with an added stressor after
acquisition to achieve higher GC-levels. Again, post-acquisition
GCs were only correlated with acquisition in men, but not in
women. This suggested a sex-specific relationship between GCs
and fear acquisition. Similarly, Merz et al. (2013a) report a
positive correlation between basal cortisol levels and amygdala
activity during fear acquisition only in men and in women taking
oral contraceptives, but not in women in their luteal cycle phase.
In a first experimental study (Jackson et al., 2006) reported
that psychosocial stress (inducing cortisol increases) enhanced
differential SCRs during both acquisition and immediate
extinction in men, but had no effect in women. However,
subsequent neuroimaging studies report the opposite effect after
a psychosocial stressor: reduced SCRs and BOLD responses
in men during acquisition and enhanced BOLD responses
after stress in women (Merz et al., 2013b). Similar results,
with higher conditioned BOLD responses in women, and
impaired responses in men were reported from the same group
(Stark et al., 2006; Merz et al., 2010) for fear acquisition after
administration of cortisol (oral, 30 mg hydrocortisone) vs.
placebo.
Cortisol effects on BOLD responses during fear acquisition
in women were shown to depend on gonadal hormone
availability: women using oral contraceptives showed enhanced
conditioned BOLD responses after cortisol, whereas cortisol
impaired responding in men and free-cycling women in their
early follicular (low E2, low P4) and mid-luteal (low to mid E2,
high P4) cycle phases (Merz et al., 2012b). But in another study
of that group, comparing men and women in their luteal phase
and women taking contraceptives, the additional experimental
factor of administering cortisol (vs. placebo) had no effect on
extinction acquisition (Merz et al., 2012a). In a recent study of
our group (Antov and Stockhorst, 2014), we tested the effect
of a psychosocial stressor that preceded fear acquisition. Fear
acquisition started in the maximum of the peripheral cortisol
peak. We examined men and free-cycling women either in the
early follicular phase (low E2, low P4) or in the mid-cycle
phase (high E2, low P4) and tested fear acquisition, extinction
acquisition (day 1) and extinction recall (day 2). We found an
interaction between stress exposure and natural E2-status within
women: in mid-cycle women, extinction recall was better when
fear acquisition had been preceded by stress, whereas the inverse
was true in early follicular women. Thus, extinction recall of
conditioned fear acquired after stress depends on estrogen status
in women. Consequently, we suggest that for extinction-based
exposure therapy in women, cycle phase and/or E2-level should
be taken into account. We assume that the mid-cycle phase (with
high E2- and low P4-levels) provides an adequate phase to re-
expose women to the aversive CSs during exposure therapy. In
healthy volunteers, exposure to aversive stimuli during this high
E2-cycle phase was also associated with less intrusive memories
(Wegerer et al., 2014).
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Considering the higher prevalence of anxiety, trauma- and
stressor-related disorders in women, and extinction deficits
under low as compared to high E2-levels (within women), one
might wonder why low levels of E2 are disadvantageous for
women, but (often) not for men who also have low levels of
circulating E2. Most importantly, one has to keep in mind that
testosterone is rapidly converted to estrogen in the brain via
aromatase. Thus, men do take advantage of estradiol actions
within the brain, although they have low levels of circulating
E2. This is supported by data showing that the inhibition
of estradiol synthesis by an aromatase inhibitor in male rats
significantly impaired extinction (Graham and Milad, 2014).
When it comes to the interaction between female sex hormones
and stress in fear conditioning studies with humans, there is
some initial evidence that there might be a higher resemblance
in the response pattern of men and naturally cycling women
in a high estrogen status than with women in a low estrogen
status (Antov and Stockhorst, 2014), or than with women
using contraceptives (Merz et al., 2012b). Here—in addition
to the above argument—one might also consider differences
in binding capacities of MRs and GRs for corticosterone, or
cortisol, respectively. These binding capacities were shown to
differ between males and females, and—within females—also
between different cycle phases (Ter Horst et al., 2012). But,
most importantly, much more studies are needed to assess the
interaction between stress and sex, or sex hormones, especially
with regard to extinction.
A Role of Male Sex Hormones and of
Hormonal Transitions in Fear Extinction
While fear extinction studies measuring female sex hormone
levels are already sparse, there are hardly any studies addressing
the role ofmale sex hormones for fear extinction. Moreover, these
remaining data are mainly based on studies using castration, not
exogenous administration of androgens.
In an early study (Anagnostaras et al., 1998), adult male
rats (age 12–17 weeks) were either castrated or sham-operated
or remained intact. Groups did not differ in their extinction
acquisition of contextual fear, or in hippocampal long-term
potentiation. Different results were obtained by McDermott
et al. (2012): castration during prepuberty (4 weeks old) as
well as thereafter (10-weeks old) resulted in an impairment of
extinction in a contextual conditioning paradigm, not in cued
conditioning, suggesting that testosterone might act to improve
fear extinction in hippocampal-dependent, not in amygdala-
mediated fear memory. In a recent fear conditioning study
with healthy men (Pace-Schott et al., 2013), testosterone levels
were also measured. Interestingly, a higher testosterone/cortisol
(T/C) ratio predicted better extinction acquisition, but only in
the morning hours (i.e., when endogenous cortisol levels are
high). The T/C ratio (not the single hormones) was negatively
correlated with the remaining CR (SCRs). Although these
data are only correlative, they encourage examining the role
of testosterone on fear extinction under stressful conditions.
Experimental studies are of interest where testosterone is
manipulated under stressful vs. control conditions. In the
meantime, it would be helpful to measure testosterone levels in
fear conditioning studies.
Another approach to study the role of sex hormones for
fear-related memory and extinction memory is to examine
developmental phases of larger hormonal changes. Again,
data are sparse. There is some evidence (recently reviewed
by Baker et al., 2014) for impaired fear extinction in
adolescents as compared to both, younger individuals as well
as adults. One explanation refers to functional changes in the
connectivity between prefrontal cortex and amygdala during this
developmental stage. Moreover, adolescence is a stage of high
vulnerability to stress (Lupien et al., 2009).
For women, pregnancy and perimenopausal stages are
additional phases of larger hormonal changes. For example, there
is a heightened risk for depression when E2 production is sharply
reduced after menopause (for an overview, see Cover et al., 2014)
and there is evidence, that estradiol replacement can improve
depressive symptoms in womenwith a history of perimenopausal
depression (e.g., Schmidt et al., 2015). More studies specifically
addressing fear extinction during developmental stages and
hormonal transitions are necessary. This might also include
conditions where estrogen receptors are blocked. This is the
case in the pharmacological adjunct therapy in estrogen-receptor
positive breast cancer patients receiving the estrogen-receptor
blocker tamoxifen.
CONCLUSION
Our review aimed at elucidating how single mediators
of the stress response (hormones, neurotransmitters, and
neuropeptides) and the entire natural stress response (covering
the sequence of the first and the second wave of the stress
response) contribute to fear extinction. Our stress approach is
guided by the idea that classical stress-response mediators are
also agents within the fear macro- and microcircuits. Thus,
explicitly investigating stress or stress-response mediators in
fear acquisition and fear extinction might mimic the natural
situation of acquiring anxiety, trauma- and stressor-related
disorders and of being re-exposed to the fear reminders during
extinction-based exposure therapy.
Concerning the mediators of the first-wave stress response
(monoamines, opioids, eCBs), animal data strongly suggest that
rapidly acting NA enhances extinction learning and extinction
memory processes; for humans, data are less conclusive and
more human studies on NA effects in extinction are warranted.
Dopaminergic as well as serotonergic signaling improves
extinction memory in animals and humans, while a number of
modifying conditions (dose, temporal spacing, targeted receptor-
subtypes, chronic vs. acute administration, gene polymorphisms)
have to be considered. An improvement of extinction also
occurs under opioid signaling and eCBs, with first evidence
also in humans. Endogenous GCs play an important part in
successful fear extinction and extinction memory. In animal
studies, data converge that GC administration can improve
extinction when the learning task is in ‘‘sync’’ with the cortisol
peak thus improving consolidation of extinction memory. In line
with animal studies, in humans GC administration combined
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with exposure therapy has shown some promise to yield a
better therapy outcome. Similar conclusions can be drawn from
diurnal effects in humans. However, the few studies with GCs
administration directly examining fear extinction in healthy
volunteers cannot back up clinical trials yet.
Considering the natural stress response, animal studies
suggest that stress impairs the consolidation/recall of fear
extinction. The impairment requires time (>24 h) and is
associated with structural changes in extinction-relevant
structures including dendritic morphology, and receptor
density. While results are mixed in humans, there is some
evidence that extinction acquisition during the first-wave stress
response (e.g., after the CPT) improves extinction recall. On the
other hand, second-wave stress before testing impairs extinction
recall.
While the prevalence of anxiety, trauma- and stressor-related
disorders is up to two times higher in women than in men,
studies addressing the level of E2 reveal better fear extinction,
especially fear extinction recall, and higher vmPFC-activity, in
cycle phases of a high as compared to low E2-level in women.
On the other hand, in PTSD-patients, behavioral fear-extinction
deficits as well as reduced vmPFC activity have been linked to
low E2-levels. There is first evidence for an interaction between
stress exposure and natural E2-status within women: in mid-
cycle women, extinction recall was better when fear acquisition
had been preceded by stress, whereas the inverse was true in
early follicular women. Thus, extinction recall of conditioned
fear acquired after stress depends on estrogen status in women.
Consequently, we suggest that for extinction-based exposure
therapy in women, cycle phase and/or E2-level should be taken
into account. In case of low E2-levels, drugs increasing dopamine
and serotonin levels might improve the success of extinction, or
exposure therapy.
We predict that behavioral and pharmacological
interventions using the mediators of the first-wave stress
response applied prior to extinction acquisition should enhance
extinction memory. For GC-related interventions (being related
to the second wave of the stress response), we should consider
that the consolidation phase of the conditioning task (i.e.,
extinction acquisition) is in ‘‘sync’’ with the GC peak in order to
take advantage of extinction-improving GC effects whereas high
GC levels at retrieval are expected to impair extinction memory
retrieval.
Since exposure therapy can be described as a form of
extinction learning, the presented data thus might also allow
predicting which of the above pharmacological interventions and
behavioral types of stress induction could constitute adjuncts
to exposure therapy. Concretely, DA- and 5-HT-reuptake
inhibitors, endorphins, eCBs, and GCs prior to extinction
(in ‘‘sync’’ with the consolidation phase) as well as stressors
strongly affecting the first-wave stress response (such as the
CPT increasing the noradrenergic tone) could be successful.
Moreover, data presented here also encourage taking cycle phase
and/or contraceptive use into account when scheduling exposure
sessions for women.
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